<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04452162</url>
  </required_header>
  <id_info>
    <org_study_id>25319</org_study_id>
    <secondary_id>834242</secondary_id>
    <nct_id>NCT04452162</nct_id>
  </id_info>
  <brief_title>Physiologic MR Imaging of Salivary Gland Tumors</brief_title>
  <acronym>PSGT</acronym>
  <official_title>Physiologic MR Imaging in Distinguishing Benign From Malignant Salivary Gland Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>McCabe Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to use advanced Magnetic Resonance Imaging (MRI) techniques to help&#xD;
      identify the difference between cancerous and non-cancerous salivary gland tumors for&#xD;
      improving treatment strategies and to aid in the prediction of disease progression.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this study is to investigate the potential utility of combined analysis of&#xD;
      parameters (Ktrans, ti and ADC) in discriminating benign from malignant salivary glands&#xD;
      tumors (SGTs). A total of 30 treatment na√Øve patients suspicious of SGT as observed on&#xD;
      clinical evaluation and prior routine CT/MRI will undergo 3T MRI. The MRI protocol will&#xD;
      include acquisition of anatomical images with and without contrast agent injection, diffusion&#xD;
      imaging and dynamic contrast enhanced-MRI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 25, 2020</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Differentiation and Progression Free</measure>
    <time_frame>6 Month after the end of treatment</time_frame>
    <description>Differentiation of malignant from benign neoplasms and progression free survival at 6 month starting from end of chemo-radiation treatment</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Salivary Gland Tumor</condition>
  <arm_group>
    <arm_group_label>Salivary Gland Tumor</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>You are being asked to complete one research MRI scan with and without contrast at least 24-48 hours after your clinical MRI/CT has shown the presence of a suspicious salivary gland tumor, prior to your scheduled upcoming surgery. MRI contrast agents act like a dye to make MRI pictures brighter and easier to read. During each MRI scan, you will have an intravenous line (IV line) placed. The IV line allows the contrast agent to be injected into your vein. A urine pregnancy test will be conducted for those of child bearing age to confirm eligibility for this study.</description>
    <arm_group_label>Salivary Gland Tumor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Possess a salivary gland lesion of 1cm3 size&#xD;
&#xD;
          -  Have no prior history of treatment for salivary gland lesion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has any prior history of cancer other than SGT&#xD;
&#xD;
          -  Has any major medical disorder such as poorly controlled diabetes mellitus, or&#xD;
             hypertension&#xD;
&#xD;
          -  Has history of prior radiation to head and neck region&#xD;
&#xD;
          -  Is pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanjeev Chawla</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lauren Karpf</last_name>
    <phone>856-266-6818</phone>
    <email>lauren.karpf@pennmedicine.upenn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lisa Desiderio</last_name>
    <phone>610-721-3365</phone>
    <email>lisa.desiderio@pennmedicine.upenn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Karpf</last_name>
      <email>lauren.karpf@pennmedicine.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Leeanne Lezotte</last_name>
      <phone>856-364-3137</phone>
      <email>leeanne.lezotte@pennmedicine.upenn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Sanjeev Chawla</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 25, 2020</study_first_submitted>
  <study_first_submitted_qc>June 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 30, 2020</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Sanjeev Chawla</investigator_full_name>
    <investigator_title>Assistant Research Professor of Radiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Salivary Gland Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

